Positive impactIPO

BLS Polymers IPO subscribed over 45x so far on Day 3; GMP jumps to 34%

Moneycontrol.com 2 hrs ago·29 Oct 2026, 4:56 am

BLS Polymers' initial public offering (IPO) has seen an overwhelming response, with applications surpassing 45 times the total offer size on the third day of bidding. This high demand has pushed the grey market premium (GMP) to 34%, indicating that the shares are trading at a significant premium to the issue price in the unlisted market.

For investors, the massive subscription level suggests strong retail and institutional interest, which is a positive signal for the listing. The high GMP further reflects the market's optimism regarding the stock's future performance post-listing. However, investors should remember that the grey market is an unofficial estimate and not a guarantee of listing gains.

Excerpt from Moneycontrol.com

The initial public offering (IPO) for BLS Polymers remained in strong demand on the last day of bidding, with the issue receiving 46.74 times subscription by 10:15 am on October 29, as per NSE data. Non-institutional investors led demand with 116.98x bids. in your portfolio by Vishal Malkan The initial public offering…
Read the original at Moneycontrol.com

Affected stocks

Bullish1 stock

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

  • Concerns BLS International Services (BLS).
  • Category: IPO.
  • AI reads the tone as positive (potentially bullish) for the stock.
  • Assessed as a significant, market-relevant update.

Why it matters

A meaningful update for BLS International Services worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at Moneycontrol.com.

More IPO news

More news

Latest headlines

More news

Aggregated from third-party sources for research. Sentiment & impact are AI-generated, indicative, not advice.